Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/1/e005924.full |
| _version_ | 1797770041937100800 |
|---|---|
| author | Susan Scott Mark Sausen Valsamo Anagnostou Jennifer Jackson Vincent Lam Joseph C Murray Lavanya Sivapalan Jenna Vanliere Canzoniero Blair Landon Benjamin P. Levy |
| author_facet | Susan Scott Mark Sausen Valsamo Anagnostou Jennifer Jackson Vincent Lam Joseph C Murray Lavanya Sivapalan Jenna Vanliere Canzoniero Blair Landon Benjamin P. Levy |
| author_sort | Susan Scott |
| collection | DOAJ |
| description | Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor burden dynamics during immunotherapy, the complexity of antitumor immune responses is not fully captured through single-feature ctDNA analyses. This underscores a need for integrative studies modeling the tumor and the immune compartment to understand the kinetics of tumor clearance in association with the quality of antitumor immune responses. Clinical applications of ctDNA testing in patients treated with immune checkpoint inhibitors have shown both predictive and prognostic value through the detection of genomic biomarkers, such as tumor mutational burden and microsatellite instability, as well as allowing for real-time monitoring of circulating tumor burden and the assessment of early on-therapy responses. These efforts highlight the emerging role of liquid biopsies in selecting patients for cancer immunotherapy, monitoring therapeutic efficacy, determining the optimal duration of treatment and ultimately guiding treatment selection and sequencing. The clinical translation of liquid biopsies is propelled by the increasing number of ctDNA-directed interventional clinical trials in the immuno-oncology space, signifying a critical step towards implementation of liquid biopsies in precision immuno-oncology. |
| first_indexed | 2024-03-12T21:16:44Z |
| format | Article |
| id | doaj.art-46803e6b30b54e82bb302fbe63077460 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-12T21:16:44Z |
| publishDate | 2023-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-46803e6b30b54e82bb302fbe630774602023-07-29T05:00:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-01-0111110.1136/jitc-2022-005924Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapySusan Scott0Mark Sausen1Valsamo Anagnostou2Jennifer Jackson3Vincent Lam4Joseph C Murray5Lavanya Sivapalan6Jenna Vanliere Canzoniero7Blair Landon8Benjamin P. Levy9The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAPersonal Genome Diagnostics, Baltimore, Maryland, USADepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USAPersonal Genome Diagnostics, Baltimore, Maryland, USAThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USACirculating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor burden dynamics during immunotherapy, the complexity of antitumor immune responses is not fully captured through single-feature ctDNA analyses. This underscores a need for integrative studies modeling the tumor and the immune compartment to understand the kinetics of tumor clearance in association with the quality of antitumor immune responses. Clinical applications of ctDNA testing in patients treated with immune checkpoint inhibitors have shown both predictive and prognostic value through the detection of genomic biomarkers, such as tumor mutational burden and microsatellite instability, as well as allowing for real-time monitoring of circulating tumor burden and the assessment of early on-therapy responses. These efforts highlight the emerging role of liquid biopsies in selecting patients for cancer immunotherapy, monitoring therapeutic efficacy, determining the optimal duration of treatment and ultimately guiding treatment selection and sequencing. The clinical translation of liquid biopsies is propelled by the increasing number of ctDNA-directed interventional clinical trials in the immuno-oncology space, signifying a critical step towards implementation of liquid biopsies in precision immuno-oncology.https://jitc.bmj.com/content/11/1/e005924.full |
| spellingShingle | Susan Scott Mark Sausen Valsamo Anagnostou Jennifer Jackson Vincent Lam Joseph C Murray Lavanya Sivapalan Jenna Vanliere Canzoniero Blair Landon Benjamin P. Levy Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy Journal for ImmunoTherapy of Cancer |
| title | Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy |
| title_full | Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy |
| title_fullStr | Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy |
| title_full_unstemmed | Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy |
| title_short | Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy |
| title_sort | liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy |
| url | https://jitc.bmj.com/content/11/1/e005924.full |
| work_keys_str_mv | AT susanscott liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT marksausen liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT valsamoanagnostou liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT jenniferjackson liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT vincentlam liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT josephcmurray liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT lavanyasivapalan liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT jennavanlierecanzoniero liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT blairlandon liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy AT benjaminplevy liquidbiopsyapproachestocapturetumorevolutionandclinicaloutcomesduringcancerimmunotherapy |